Abstract
Invasive Pulmonary Aspergillosis (IPA), mainly caused by the saprophyte Aspergillus fumigatus, is a clinical condition associated with high mortality rates depending on the immunological status of the host. Caspofungin (CSP), yet the second choice of therapy, is an important echinocandin for the treatment of IPA, targeting the fungal cell wall, promoting growth inhibition but favoring an …